Light therapy combo targets deadly bile duct cancer in new trial

NCT ID NCT07398339

Recruiting now Disease control Sponsor: Shanghai Guangsheng Biopharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a new approach for people with advanced bile duct cancer that has caused a blockage. The treatment combines a light-activated drug (sodium porphyrin) with standard chemotherapy (gemcitabine and cisplatin). The goal is to see if this combination can help patients live longer and control the cancer. The study will enroll 30 participants and measure survival at 6 months as the main outcome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sodium porphyrin injection (photosensitizer) used in photodynamic therapy, plus gemcitabine and cisplatin chemotherapy
What this could lead to: If successful, this could offer a new treatment option to help people with advanced bile duct cancer live longer and control the disease.
What could go wrong: This is an early phase 2 trial with only 30 people, so results may not apply to everyone. The treatment may cause side effects like light sensitivity and chemotherapy-related toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms extrahepatic bile duct carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCERS (BTC)

Contacts and locations

Locations

No. 266, Trumpet Vine Road
RECRUITING

Shanghai, Pudong New Area, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.